Gu SZ - Search Results

1

Comprehensive biomechanical and anatomical atherosclerotic plaque metrics predict major adverse cardiovascular events: A new tool for clinical decision making.

Gu SZ, Ahmed ME, Huang Y, Hakim D, Maynard C, Cefalo NV, Coskun AU, Costopoulos C, Maehara A, Stone GW, Stone PH, Bennett MR. Gu SZ, et al. Atherosclerosis. 2024 Mar;390:117449. doi: 10.1016/j.atherosclerosis.2024.117449. Epub 2024 Jan 11. Atherosclerosis. 2024. PMID: 38262275 Free PMC article.

2

Heterogeneous plaque-lumen geometry is associated with major adverse cardiovascular events.

Gu SZ, Huang Y, Costopoulos C, Jessney B, Bourantas C, Teng Z, Losdat S, Maehara A, Räber L, Stone GW, Bennett MR. Gu SZ, et al. Eur Heart J Open. 2023 Apr 13;3(3):oead038. doi: 10.1093/ehjopen/oead038. eCollection 2023 May. Eur Heart J Open. 2023. PMID: 37143612 Free PMC article.

3

Plaque Structural Stress: Detection, Determinants and Role in Atherosclerotic Plaque Rupture and Progression.

Gu SZ, Bennett MR. Gu SZ, et al. Front Cardiovasc Med. 2022 Jul 7;9:875413. doi: 10.3389/fcvm.2022.875413. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35872913 Free PMC article. Review.

4

High-intensity statin treatment is associated with reduced plaque structural stress and remodelling of artery geometry and plaque architecture.

Gu SZ, Costopoulos C, Huang Y, Bourantas C, Woolf A, Sun C, Teng Z, Losdat S, Räber L, Samady H, Bennett MR. Gu SZ, et al. Eur Heart J Open. 2021 Nov 17;1(3):oeab039. doi: 10.1093/ehjopen/oeab039. eCollection 2021 Nov. Eur Heart J Open. 2021. PMID: 35919883 Free PMC article.

5

Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.

Tufaro V, Serruys PW, Räber L, Bennett MR, Torii R, Gu SZ, Onuma Y, Mathur A, Baumbach A, Bourantas CV. Tufaro V, et al. Among authors: gu sz. Cardiovasc Res. 2023 Mar 17;119(1):121-135. doi: 10.1093/cvr/cvac051. Cardiovasc Res. 2023. PMID: 35394014 Free article. Review.

6

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.

7

[A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese patients with advanced solid tumors].

Liu RR, Gu SZ, Zhou T, Lin LZ, Chen WC, Zhong DS, Liu TS, Yang N, Shen L, Xu SY, Lu N, Zhang Y, Gong ZL, Xu JM. Liu RR, et al. Among authors: gu sz. Zhonghua Zhong Liu Za Zhi. 2023 Oct 23;45(10):898-903. doi: 10.3760/cma.j.cn112152-20220530-00373. Zhonghua Zhong Liu Za Zhi. 2023. PMID: 37875426 Clinical Trial. Chinese.

8

Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.

Zhao M, Guo Z, Zou YH, Li X, Yan ZP, Chen MS, Fan WJ, Li HL, Yang JJ, Chen XM, Xu LF, Zhang YW, Zhu KS, Sun JH, Li JP, Jin Y, Yu HP, Duan F, Xiong B, Yin GW, Lin HL, Ma YL, Wang HM, Gu SZ, Si TG, Wang XD, Zhao C, Yu WC, Guo JH, Zhai J, Huang YH, Wang WY, Lin HF, Gu YK, Chen JZ, Wang JP, Zhang YM, Yi JZ, Lyu N. Zhao M, et al. Among authors: gu sz. Hepatol Int. 2024 Feb;18(1):4-31. doi: 10.1007/s12072-023-10599-6. Epub 2023 Oct 21. Hepatol Int. 2024. PMID: 37864725

9

Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction (CODE-AAMI): Protocol for a Randomized Placebo-Controlled Trial.

Wu YJ, Deng B, Wang SB, Qiao R, Zhang XW, Lu Y, Wang L, Gu SZ, Zhang YQ, Li KQ, Yu ZL, Wu LX, Zhao SB, Zhou SL, Yang Y, Wang LS. Wu YJ, et al. Among authors: gu sz. Chin J Integr Med. 2023 Dec;29(12):1059-1065. doi: 10.1007/s11655-023-3648-6. Epub 2023 Sep 1. Chin J Integr Med. 2023. PMID: 37656413

10

Correlation of Change in Macular Thickness With Change in Visual Acuity in Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.

Nanegrungsunk O, Gu SZ, Bressler SB, Du W, Amer F, Moini H, Bressler NM. Nanegrungsunk O, et al. Among authors: gu sz. J Vitreoretin Dis. 2022 Jul 27;6(4):284-289. doi: 10.1177/24741264221099429. eCollection 2022 Jul-Aug. J Vitreoretin Dis. 2022. PMID: 37007927 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page